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Abstract: Cardiovascular diseases are a large contributor to causes of early death in
developed countries. Some of these conditions, such as sudden cardiac death and atrial
fibrillation, stem from arrhythmias—a spectrum of conditions with abnormal electrical
activity in the heart. Genome-wide association studies can identify single nucleotide
variations (SNVs) that may predispose individuals to developing acquired forms of
arrhythmias. Through manual curation of published genome-wide association studies, we
have collected a comprehensive list of 75 SNVs associated with cardiac arrhythmias. Ten
of the SNVs result in amino acid changes and can be used in proteomic-based detection
methods. In an effort to identify additional non-synonymous mutations that affect the
proteome, we analyzed the post-translational modification S-nitrosylation, which is known
to affect cardiac arrhythmias. We identified loss of seven known S-nitrosylation sites due
to non-synonymous single nucleotide variations (nsSNVs). For predicted nitrosylation sites
we found 1429 proteins where the sites are modified due to nsSNV. Analysis of the
predicted S-nitrosylation dataset for over- or under-representation (compared to the
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complete human proteome) of pathways and functional elements shows significant
statistical over-representation of the blood coagulation pathway. Gene Ontology (GO) analysis
displays statistically over-represented terms related to muscle contraction, receptor activity,
motor activity, cystoskeleton components, and microtubule activity. Through the genomic
and proteomic context of SNVs and S-nitrosylation sites presented in this study,
researchers can look for variation that can predispose individuals to cardiac arrhythmias.
Such attempts to elucidate mechanisms of arrhythmia thereby add yet another useful
parameter in predicting susceptibility for cardiac diseases.
Keywords: cardiac arrhythmia; SNP; genome-wide association; proteomics; next-generation
sequencing; S-nitrosylation; cysteine; nsSNV; biocuration

1. Introduction
Cardiac arrhythmias encompass a range of conditions in which the normal rhythm of the heart is
disrupted. The conditions include sudden cardiac death (SCD) and atrial fibrillation (AF), the most
common form of arrhythmia [1,2]. The causes of arrhythmias such as AF are multifaceted and this
presents difficulties in their treatment [3]. The number of Americans afflicted with arrhythmia is
expected to increase as the population ages. Consequently, understanding the exact mechanisms of the
disease and developing treatments is important.
DNA sequencing has evolved from its beginnings in the Sanger method. Now, next-generation
sequencing (NGS) technologies allow the sequencing of millions of fragments of DNA in unison from
a single sample. This process of parallel sequencing allows the whole genome to be sequenced in less
than a day and is expected to be used in clinics in the near future [4]. Advances in DNA sequencing and
genome-wide association studies are impacting detection, management, and treatment of diseases [5–8].
Several studies have investigated mutations and their associations with cardiac diseases. For example,
long QT-syndrome (LQTS) is a disease characterized by prolonged repolarization of the heartbeat [9].
Research has shown that LQTS stems from mutations in genes encoding cardiac ion channels [10].
Over 100 mutations have been identified in 5 separate cardiac ion channel genes [9,10]. Other cardiac
channelopathies, or disorders of the heart channel, affect normal cardiac rhythm in individuals [11].
Heritable cardiac arrhythmias, acquired from genetic alterations of these ion channels involved in
cardiac heart rhythm, predispose affected individuals to sudden death [11]. Research on sudden cardiac
death (SCD), which mainly results from severe ventricular arrhythmias, shows that a majority of
mutations are found in the coding regions of ion channel units and key regulatory proteins. These
mutations often lead to ion channel dysfunctions or affect biophysical properties of ion channels
involved in normal heart function [12]. Further, computer modeling and simulations of cardiac
myocytes have enabled scientists to represent variations in gene expression and allows them to
reconstruct the effects of mutations characterized by functional changes in proteins [13]. Similar to
DNA sequencing, proteomics technologies are also rapidly improving [14]. It is now possible to
use proteomic technologies in conjunction with genomic technologies to detect and/or validate
nsSNVs [15,16]. Such validation is critical to distinguish between inherited variations, somatic DNA

Genes 2014, 5

256

and RNA modifications [17]. Therefore, having a list of amino acid changes that are potentially related
to a specific disease can be of immense value as priority targets for proteomic validation.
One method for studying arrhythmias is investigating the genetic roots of the condition. This report
presents the SNVs discovered or confirmed to have associations with arrhythmia over the past twenty
years through genome-wide association and replication studies. Table 1 shows ten amino acid
changing mutations, which can be detected using modern proteomic technologies [18]. While the
variations are contained within a range of genes, the report further investigates two genes in particular.
The first is NOS1AP, the most represented gene in Table S1, with 12 SNPs. The second gene is
KCNN3, which hosts one of the exonic variants.
Table 1. Summary of variant information from Table S1.
Gene

Number of Variations

Chromosome Number

Amino Acid Change

Gene Description

SCN10A

2

3

V1073A

Sodium ion channel
Cardiovascular helix-loop-helix factor 1

HEY2

1

6

0

SCN5A

5

3

S1103Y, H558R

Sodium ion channel

TBX5

1

12

0

T-box transcription factor

NOS1AP

12

1

0

Nitric oxide synthase 1 adaptor protein

ATP1B1

2

1

0

Sodium/potassium-transporting ATPase subunit beta-1

ZFHX3

3

16

0

Zinc finger homeobox protein 3

KCNN3

3

1

N44N

Small conductance potassium channel

KCNJ2

2

17

0

Potassium ion channel

XYLB

3

3

0

Energy metabolism

EXOG

3

3

0

Endonuclease

ACVR2B

3

3

0

Activin Receptor

RNF207

1

1

G603A

Ring finger protein

PLN

2

6

0

Cardiac Muscle

KCNH2

5

7

K897T, K557T

Potassium voltage gated channel

KCNQ1

4

11

G643S

Potassium voltage gated channel

LITAF

1

16

0

DNA binding protein

NDRG4

1

16

0

Mitogenic signalling

AGTR1

1

3

0

Angiotensis II receptor

KNG1

1

3

0

Kininogen

KCNE1

3

21

D85N, S38G

Potassium voltage gated channel

KCNE4

1

2

D196E

Potassium voltage-gated channel

In an attempt to identify more amino acid changing variations potentially connected to the disease,
we investigated the post-translational modification (PTM) nitrosylation. S-nitrosylation involves
covalent attachment of Nitric Oxide (NO) to the thiol side chain of cysteine to form an S-nitrosothiol
(SNO) [19]. NO is a well-known signaling molecule in the cardiovascular system and its role in
cardiovascular diseases has been established [20]. S-nitrosylation is a reversible and selective PTM
which regulates protein activity, cellular signal transduction, localization, and stability [19,21].
Modified levels of SNO proteins in the blood have been associated with high risks in patients with
cardiovascular diseases [19]. Several studies have investigated these associations. Massy et al. found
elevated plasma SNO levels in patients undergoing chronic hemodialysis predict cardiovascular
outcomes [22]. Another study investigated NO as an endocrine vasoregulator in red blood cells and the
potential impact NO plays in congestive heart failure [23]. In addition to nitrosylation other PTMs,
such as glycosylation and phosphorylation, are also known to maintain the cardiac rhythm [12].
Current studies examine the association between acquired arrhythmias and PTMs of the cardiac
sodium channel, which is involved in cardiac action potentials [24]. Cutler et al. demonstrated that
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neuronal nitric oxide synthase (NOS1) inhibition in the intact heart, along with the presence of increased
myocardial Ca2+, increases an individual’s chances of Ca2+-mediated triggered arrhythmias [25]. Based
on the aforementioned connections of nitrosylation and heart disease, we analyzed experimental and
predicted loss of S-nitrosylation sites that are affected by nsSNVs.
2. Experimental
Manual curation of scientific articles retrieved using PubMed database [26] produced the 75 SNPs
shown in Table S1. The articles selected from the PubMed database were found using search terms
that included “Arrhythmia”, “Genome-wide”, “Association”, “Study”, “Cardiac”, and “SNP”. The
articles published in the last 20 years were examined for reports of SNVs associated with cardiac
arrhythmias. In these articles, SNVs discovered to have statistically significant associations with
cardiac arrhythmias were added to the data shown in Table S1. To ensure consistency, articles that
reported SNVs as a result of meta-analysis studies were not included in the list. Only SNVs that were
discovered or confirmed in studies by the publishing group were eligible for inclusion. Of those SNVs,
only those with statistically significant associations with cardiac arrhythmias were included. After
extraction, background information on each SNV was collated from the Single Nucleotide
Polymorphism Database or dbSNP [26] (Tables 1 and S1). This public domain archive hosts a broad
collection of simple genetic variations.
The seven experimentally verified S-nitrosylated cysteine sites that are affected by nsSNVs (Table 2)
were obtained through mapping of S-nitrosylated proteins to the variations. These S-nitrosylated proteins
were obtained from a literature review of endogenously S-nitrosylated proteins by Gould et al. [27].
Table 2 displays the proteins affected by the nsSNVs. Prediction of S-nitrosylation sites was performed
as follows: the complete human proteome was obtained from UniProtKB/Swiss-Prot and GPS-SNO
tool was used to predict N-nitrosylation sites [28]; pairwise alignments between Homo sapiens proteins
and Mus musculus, Drosophila melanogaster, Arabidopsis thaliana and Saccharomyces cerevisiae
proteins was performed followed by mapping of nsSNVs from SNVDis [29] to create a table that
included predicted S-nitrosylation sites, conserved sites among the species and variation. Enrichment
analysis was performed to identify over- or under-represented pathways or GO terms in the protein
dataset, compared to their occurrence in the complete human proteome (Table 3). The expected
occurrence of a pathway or GO term was calculated based on the actual number of times it was present
in the human proteome [29,30]. Over- and under-represented pathways and processes were compared
through significance in p values calculated based on methods described earlier [31].
Table 2. Loss of experimentally confirmed S-nitrosylation sites by nsSNVs.
Protein name

Position

Variation

Subseq

Ortholog

Species

Alpha-enolase

357

c->y

qackl

P21550

Mouse

Cysteine and glycine-rich protein 3

58

c->g

iyckv

P50462

Mouse

Myosin-6

949

c->y

decse

Q02566

Mouse

Catenin beta-1

619

c->y

vlcel

Q02248

Mouse

Elongation factor 1-alpha 1

234

c->w

ldcil

P10126

Mouse

Myelin proteolipid protein

220

c->y

kvcgs

P60202

Mouse

E3 ubiquitin-protein ligase XIAP

90

c->y

pncrf

A2BGY6

Mouse
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Table 3. Functional analysis of predicted cysteine S-nitrosylation sites with mutations.
Analysis

Functional object

Observed

Expected

+/−

p value

PANTHER Pathways

Blood Coagulation

13

3.82

+

3.64E-29

Receptor (includes G-protein coupled receptor)

190

123.24

+

4.13E-07

PANTHER Protein Classification

GO Biological Process

Cytoskeletal protein

98

64.03

+

5.46E-03

Defense/immunity protein

72

46.53

+

4.48E-02

Muscle contraction

73

37.48

+

1.92E-05

Neurological system process

188

128.53

+

2.04E-05

Cellular component organization

131

84.15

+

9.63E-05

Receptor activity (includes G-protein coupled receptor activity)

190

124.18

+

6.02E-07

GO Molecular Function

GO Cellular Component

Motor activity

26

9.52

+

1.05E-03

Structural constituent of cytoskeleton

98

64.03

+

4.52E-03

Cytoskeleton

98

64.03

+

1.09E-03

Microtubule

35

17.70

+

5.89E-03

Intracellular

107

76.44

+

1.36E-02

3. Results and Discussion
Table S1 is a resource for researchers or clinicians to quickly identify SNVs associated with
arrhythmias. The inclusion of information such as flanking base pairs and exact chromosomal position
for each of the variants in Table S1 expedites the process of testing patients if whole genome, targeted
sequencing data or proteomics data is available. Below are details of some of the genes and variations
associated with them that correlate to arrhythmia.
3.1. NOS1AP
As shown in Table 1, the gene with the most variations was NOS1AP. The NOS1AP gene is located
on chromosome 1 at q23.3. The gene codes for a regulatory protein—carboxyl-terminal PDZ ligand of
neuronal nitric oxide synthase [32]. The protein influences the activity of nitric oxide synthase (NOS).
When the NOS1AP protein is expressed in the heart, cardiac repolarization is typically accelerated.
The NOS1AP enzyme inhibits L-type calcium channels [33]. The closing of L-type calcium channels
inhibits the influx of Ca2+ current. Consequently, intracellular calcium concentrations do not increase,
and the beta-adrenoreceptor stimulation of the heart is suppressed. This system, starting with the
expression of the NOS1AP protein and resulting in a change in the electrophysiology of the heart,
helps explain the role of NOS1AP variants with QT interval duration. QT interval is a measure of
cardiac repolarization and a common biomarker of arrhythmia. The QT interval is estimated to be 30%
heritable [34]. Studies have shown that the noncoding variants in NOS1AP are influential [35]. This is
consistent with the data in Table 1 where all of the NOS1AP variants are intronic. The genome-wide
association study by Arking et al. investigated 200 individuals and found associations in these
individuals between QT interval length and the common variants in the noncoding regions of
NOS1AP. These findings were replicated in a community of Old Order Amish [36].
Due to the complexity of the biological system, it is difficult to predict how these intronic variants
specifically influence the malfunction or mis-regulation of the NOS1AP gene. However, the presence
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of resources such as Table S1 can help organize further inquiries into the role of intronic variants in
disease development.
3.2. KCNN3
The SNV rs1131820 is a synonymous SNV found in the KCNN3 gene. The KCNN3 gene is located
on chromosome 1q21 and is responsible for coding the protein SK3. The protein SK3 belongs
to a family of proteins that operate as calcium activated potassium channels. Specifically, SK3 is a
small-conductance calcium activated potassium channel [37]. This indicates that SK3 is voltage
insensitive and the opening of the channel is instead reliant on the presence of calcium ions. The
protein plays a role after hyper-polarization, a calcium dependent process that is executed after the
firing of an action potential in a neuron. A variant in KCNN3 may influence the regulation or function
of the SK3 protein. Reduced efficacy of the SK3 protein can inhibit influx of potassium ions through
the potassium channel across a membrane. This can disrupt firing of the neuron. Consequently,
KCNN3 variants expressed in regions such as the brain or the heart can have significant consequences
on those delicate biological systems.
In the heart, a KCNN3 variant was shown to have an association with lone atrial fibrillation. This
SNP rs1131820, shown in Table 1 is synonymous. This indicates that there is no consequent change in
amino acid from the base pair mutation. One would anticipate that without a change in the amino acid,
the effects of a variation would not manifest. However, in this circumstance, a carrier of the two major
alleles GG at rs1131820 had an odds ratio of 2.85 (95% CI 1.13–7.18, p = 0.026) for lone atrial
fibrillation when compared to carriers of the minor allele AA [38]. This suggests that carriers of the
two major alleles GG are nearly three times more likely to develop lone atrial fibrillation. It is still
unclear how a synonymous SNP can drastically increase the likelihood of an individual developing a
disease or condition. Recent research has shown that these silent variations may affect the affinity of
RNA binding proteins for mRNA, the splicing of pre-mRNA, and the stability of pre-mRNA [39–41].
This, in turn, may compromise the structure of the mRNA, and consequently influence protein
formation, efficacy or concentration [42,43]. Once protein function or concentration has been altered,
action potential firing in the heart can be disrupted and lead to the development of atrial fibrillation.
3.3. Analysis of Exonic SNVs
The exonic SNVs shown in Table 1 were explored further using the NHLBI Exome Sequencing
Project (ESP). This project is a collaborative effort between various institutions and research hospitals
to use NGS of the human exome to discover new genes and the mechanisms through which they
influence the development of heart, blood, and lung disorders. The project expands across diverse
populations and facilitates the sharing of conclusions and datasets throughout the scientific community
(Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA, USA [44].
11 exonic SNVs in the ESP database were searched. The new noteworthy information that the ESP
database yielded for each SNV included variation impact analysis values. This value helps predict the
likely impact of an amino acid substitution on protein structure and function [45]. The PolyPhen-2
scores for the variants ranged from benign 0.0 for the SNVs rs6795970, rs180514, rs1805127,
rs12621643, and rs1800172—to possibly damaging 0.952 for SNV rs1805123. A score of benign
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suggests that the amino acid substitutions in each of these SNPs have no serious consequences on
protein function. However, rs679570 was associated with time changes in the electrical cycles of the
heart and an increased risk of heart block [46]. Conversely, rs846111 was associated with changes in
the Q-T interval of the heart [47]. Finally, although rs113180 was not assigned a PolyPhen-2 score,
this synonymous SNP is associated with a nearly three times higher likelihood of an individual
developing lone atrial fibrillation [38].
3.4. Non-Synonymous Variation
Table 1 shows ten nsSNVs, one is a variant in a gene that encodes a ring finger protein, the other
nine SNVs are found in genes that encode sodium ion channels or potassium voltage-gated channels.
The two sodium ion channel genes are SCN10A and SCN5A. They are the type X and type V
voltage-gated sodium channels, respectively. Table 1 shows that the SCN5A gene hosts two nsSNVs.
The first is an amino acid substitution from serine to tyrosine at position 1103. The second is an amino
acid substitution from histidine to arginine at position 558. The gene SCN10A contains the SNV
rs6795970, an A/G base pair polymorphism at chromosome 3 position 38766675. This mutation in the
exonic region results in an amino acid change from valine to alanine at position 1073. The specific
voltage-gated sodium channel is labeled Nav1.8 and the protein is more commonly known for its role
in facilitating cold perception in afferent nociceptive fibers [1]. Despite the association of this SNV
with cardiac arrhythmias, the role of the Nav1.8 sodium channel in the electrophysiology of the
heart is still uncharacterized [2]. The influence of the amino acid substitution on the function of the
voltage-gated sodium channel is still unknown.
The genes found with nsSNVs that code for potassium voltage-gated channels are KCNE1,
KCNH2, KCNQ1, and KCNE4. KCNH2 and KCNQ1, found in chromosome 7 and 11 respectively,
are genes whose variants have been associated with long QT syndrome [48,49]. In KCNH2, the two
nsSNVs are substitutions from lysine to threonine at amino acid positions 897 and 557. In KCNQ1, the
variant results in an amino acid substitution from glycine to serine at position 643. The final two
genes, KCNE1 and KCNE4 are found on chromosome 21 and 2, respectively. They belong to the
KCNE family of genes, which encode trans-membrane proteins with a wide array of functions. Each of
these genes contains non-synonymous SNPs that have associations with cardiac arrhythmias [50,51].
The RNF207 gene codes for a ring finger protein and contains the variant rs846111. This variant is
found on chromosome 1 position 6279370. RNF207 codes for ring finger protein 207. The protein plays
a role in intracellular zinc ion binding [3]. The specific in vivo function of the protein is still unknown.
Although it is known that the variation translates to a shift of glycine to alanine at position 603, the
specific influences of this amino acid substitution on the protein’s function are not yet understood.
3.5. Nitrosylation
PTMs such as glycosylation, phosphorylation, and nitrosylation help maintain cardiac rhythm, and
modulate gating, localization, and cardiac channel expression levels [12]. To identify additional
variations potentially connected to cardiac arrhythmias, we investigated the PTM Nitrosylation. Nitric
oxide (NO) is synthesized by a majority of cardiac cell types and plays a vital role in regulating cardiac
function [52]. The effects of NO are moderated by S-nitrosylation, which is the covalent modification
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of a protein cysteine thiol by an NO group to generate an S-nitrosothiol (SNO) [53]. The fundamental
roles for S-nitrosylation have been involved in major functions of NO in the cardiovascular system [53].
Gould et al. performed a literature search for S-nitrosylated proteins in vivo [27]. The 233
S-nitrosylated proteins they compiled display an over-representation of mitochondrial proteins, a
significant proportion involved in the generation of precursor metabolites and energy, and pathological
conditions associated with an overproduction of NO, which results in inappropriate S-nitroyslation and
dysfunction of proteins [27]. To further understand which nitrosylated proteins were affected by
variation, we mapped the nitrosylation sites of 233 S-nitrosylated proteins to non-synonymous
variations. We found seven cysteines that have loss of S-nitrosylation sites due to nsSNVs (Table 2).
Myosin, a motor protein listed in Table 2, plays a role in regulation of the heartbeat and cardiac
function. Studies have shown that mutations of the cardiac myosin gene are the most common cause of
inherited hypertrophic cardiomyopathy [54]. Nearly 200 disease-associated myosin mutations have
been identified since the discovery of the E cardiac myosin heavy-chain (E-MHC) gene missense
mutation’s role in hypertrophic cardiomyopathy [54,55]. E-MHC is a sarcomeric protein expressed in
the right and left ventricles of the heart, as well as many skeletal muscles [56]. The precise location of
the mutation or alteration of the myosin gene appears to influence the survival of patients; further
investigation of this variation may lead to better prognostics for people affected by the mutation [55].
The current list of experimentally verified nitrosylation sites is not comprehensive. Table S2
contains the list of 1429 proteins which have conserved cysteines across eukaryotic species predicted
to be S-nitrosylated and affected by nsSNPs and Figure 1 shows that several of these sites have
nsSNVs. To better understand the distribution of predicted S-nitroyslation sites with conserved motifs,
we analyzed the dataset to observe if there was over- or under-representation (compared to the
complete human proteome) of pathways and functional elements/biological processes. An initial analysis
using the UniProtKB/Swiss-Prot keyword ‘Disease’ showed that the keyword was over-represented in the
predicted list of S-nitrosylated proteins (observed: 356; expected: 196.96; p-value: 3.64E-29). The highly
significant p value proved that there are a higher number of disease proteins that are present in Table S2.
For several of the known or predicted S-nitrosylation sites that are lost due to nsSNVs we were able to
identify diseases associated with these variations (examples—dbSNP id: rs104894204, gene: CSRP3,
UniProt AC/position/variation: P50461/58/c->g, disease: familial hypertrophic cardiomyopathy type 12;
dbSNP id: rs121909300, gene: OXCT1, UniProt AC/position/variation: P55809/456/c->f, disease:
succinyl-coa-3-ketoacid-coa transferase deficiency; dbSNP id: rs121909267, gene: CASR, UniProt
AC/position/variation: P41180/131/c->w, disease: familial isolated hypoparathyroidism). S-nitrosylation
has not yet been directly connected to these diseases and hence sites such as these (additional ones
available in Table S2) are ideal for further biochemical analysis to elucidate the role of S-nitrosylation
in cardiac and other diseases.
The PANTHER gene ontology database [57] determined if the predicted loss of S-nitrosylation sites
affected by nsSNVs were statistically enriched with a particular molecular function or biological
process. Over- and under-representation of PANTHER Pathways, Protein Classification, and Gene
Ontology (GO) terms in the predicted list of mutated cysteines, provided an overview of possible
effects these non-synonymous variations might have. Table 3 contains the results of the PANTHER
statistical overrepresentation test. The major pathway identified as over-represented is blood
coagulation (observed: 13; expected: 3.82; p-value: 3.64E-29). Atrial Fibrillation, a common type of
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arrhythmia, can lead to blood clots and other complications. Antithrombotic prophylaxis for stroke, a
major risk of atrial fibrillation, is associated with an increased risk of bleeding [58].
Figure 1. Percentage of predicted S-nitrosylated proteins and sites and the ones which are
conserved across mouse, fly, plant or yeast and the nsSNVs mapped to these proteins and
sites. Details are available in Table S2.
Number of Proteins

100
90
80
70
60
50
40
30
20
10
0

Number of Sites

Predicted Snitrosylation

Predicted-conserved Variation at predictedS-nitrosylation
conserved position

Cysteines not known to
Predicted-conserved SPredicted S-nitrosylation
be S-nitrosylated
nitrosylation

Variation at predictedconserved position

Number of
Proteins

20261

14054

11718

1429

Number of
Sites

260120

33327

24578

1598

The major broad terms for Gene Ontology (GO) Biological Processes that were statistically
over-represented were Muscle Contraction, Neurological System Process, and Cellular Organization.
For GO Molecular Function, the major terms included receptor activity (includes G-protein coupled
receptor activity), motor activity, and structural constituent of cytoskeleton. The cytoskeleton was the
top over-represented GO cellular component (p-value: 1.09E-03). The cytoskeleton of cardiac myocytes
consists of actin filaments, intermediate filaments, and alpha- and beta-tubulin that form the
microtubules by polymerization [59]. Studies have shown that the extra-sarcomeric cytoskeleton plays
a part in the growth response of the heart and in the pathogenesis of cardiomyopathies [60]. Acquired
forms of heart failure have displayed an altered expression of cytoskeletal proteins [61].
Microtubules were also statistically over-represented in GO cellular components (p-value: 5.89E-03).
Recent studies have investigated the role of microtubules in cardiac arrhythmias. In hypertrophy and
heart failure, the accumulation of microtubules disrupts sarcomere motion, contributing to declining
ventricular compliance [61]. Microtubule integrity has been linked to cardio-protection, while
microtubule disruption has been associated in the response to ischemia in cardiac myocytes [62].
3.6. Next-Generation Sequencing and Variation
As the cost of exome sequencing decreases, the use of patient exome sequencing will increase as a
diagnostic tool. Here we describe a possible workflow for identifying variation from NGS data using a
High-performance Integrated Virtual Environment (HIVE), a cloud-based environment [63].
The FASTA sequences surrounding a SNV are obtained from dbSNP by querying the database
using the dnSNP ID from Table S1 followed by “Send to” option and selecting “File” at “Choose
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Destination” ≥ “FASTA”. This file is then uploaded to HIVE and used as a reference to which NGS
data from an individual can be mapped (for additional details see help section on HIVE). Once the
input files (FASTA file downloaded from dbSNP and NGS data obtained from an individual) are
selected then HIVE-hexagon, a sequence mapping algorithm, is used with default parameters to map
the NGS reads to the FASTA record which has the SNV in it. Once the mapping is complete then
HIVE-pentagon, a SNV profiling tool, is used to identify all the variations in the individual.
Visualization of the mapping results provides an easy overview of the variations present in the
individual an example of which is shown in Figure 2.
Figure 2. HIVE interface showing results obtained from SNV profiling of human exome
reads mapped to FASTA sequence surrounding a SNV. (A) Overall coverage result with
the 603 position showing variation. (B) Reads mapped to the reference with the yellow
highlighting the column selected. (C) Only variations are shown in this panel.
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4. Conclusions
We expect that as whole genome sequencing becomes more affordable, genetic testing will play a
larger role in the diagnosis of cardiac disorders, and that resources such as Table S1 will become more
valuable and common place. In addition to their capacity to sequence whole genomes, the NGS
platforms are capable of targeted sequencing. Table S1 also contains nucleotides that are upstream and
downstream of each variant. This information allows researchers or physicians to quickly generate
libraries of nucleic acids as the primary step in creation of a template. There is currently no quick and
easy way to compile a list of variations that have associations with a condition or disease. This table
provides a solution for this gap through manual curation. Rather than having physicians and
researchers sift through papers to isolate SNPs that are associated with diseases, they can simply create
a library of nucleic acids using the information contained in the table. These libraries can then be
clonally amplified and their fragments can be prepared specifically per the requirements of the various
NGS platforms. The list of these variations is also available from the BioMuta database [64]. It is
important to note that DNA variants are rarely the sole determinant of whether an individual will
acquire a disease or not. Consequently, it is important that healthcare workers as well as patients
remember that these SNVs are a single parameter in a complex biological system. An additional
danger that arises from sequencing patients as a diagnostic tool is the incidental discovery of presumed
deleterious mutations [65].
In an attempt to identify more variants potentially connected to the disease, we investigated the
post-translational modification nitrosylation in depth. Many studies have examined potential
associations between acquired arrhythmias and post-translational modifications, such as glycosylation,
phosphorylation, and nitrosylation. Tables 2 and 3 provide both experimental and predicted approaches
for discovering loss of S-nitrosylation sites that are affected by nsSNVs and details of the amino acid
changes are present in Table S2. This information can be used to develop proteomic strategies for
variation detection.
Supplementary Materials
Table S1. Single-nucleotide polymorphisms associated with cardiac arrhythmias extracted
from publications.
Table S2. Predicted S-nitrosylation sites, which are conserved in other eukaryotes and have
non-synonymous variations.
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